ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Molsidomin-Mepha® 8 retard:Mepha Pharma AG
Complete information for professionalsDDDPrint 
Galenic Form / Therapeutic GroupComposition.EffectsPharm.kinetikIndication.UsageRestrictions.Unwanted effects
Interactions.OverdoseOther adviceSwissmedic-Nr.Last update of information 
C01DX12 - MolsidomineATC-DDD Version 2016. Source: WHO
C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C01 - Cardiac Therapy
 
C01D - Vasodilators Used in Cardiac Diseases

This group comprises preparations used in ischemic heart diseases. See also C02 - Antihypertensives, C03 - Diuretics, C04 - Peripheral vasodilators, C07 - Beta blocking agents, C08 - Calcium channel blockers and C09 - Agents acting on the renin-angiotensin system.
Combinations with cardiac glycosides, see C01A.
Combinations with rauwolfia alkaloids, see C02AA.
Combinations with beta blocking agents, see C07.
Combinations with calcium channel blockers, see C08.

C01DX - Other Vasodilators Used in Cardiac Diseases

This group comprises vasodilators used in cardiac diseases, which cannot be classified in the preceding groups.

C01DX12 - Molsidomine
2025 ©ywesee GmbH
Settings | Help | Login | Contact | Home